APA (7th ed.) Citation

GC, I., I, A., MJ, T., J, D., M, A., JS, B., . . . EM, S. (2025). Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(1), 75. https://doi.org/10.1200/JCO.24.00826

Chicago Style (17th ed.) Citation

GC, Issa, et al. "Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 1 (2025): 75. https://doi.org/10.1200/JCO.24.00826.

MLA (9th ed.) Citation

GC, Issa, et al. "Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 1, 2025, p. 75, https://doi.org/10.1200/JCO.24.00826.